Scholars Central

Research articlePublished 26 Apr 2023

Effects of a Natural Extract on Molecular Signature in Post-Acute Sequelae SARS-CoV-2 (PASC) Infection: A Quasi-Experimental Study

Authors: Alben Sigamani, Sangeetha Sampath Kumar, K Sunil Naik

Diversity & Equality in Health and Care

Volume 21 · Issue 4 · Pages 1–8

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Aim: Long COVID becomes an economic and public health challenge that affects the daily activities and quality of life of millions of COVID-19 survivors. Long COVID symptoms, particularly persistent fatigue, appear to be associated with a chronic state of inflammation. Based on the anti-inflammatory property of Tinospora cordifolia, CelWel has the potential to improve the symptoms of Long COVID. The purpose of this study was to assess the efficacy and safety of CelWel in patients with Long COVID. Methods: This was a non-randomized, open-label pilot study with 15 COVID-19 infected male and female subjects who had Long COVID symptoms. Subjects were given 0.4 mL of the CelWel supplement 4-6 times per day for 14 days. The severity of Long COVID symptoms was assessed using the Fatigue Severity Scale Questionnaire (FSSQ) and the Yorkshire COVID-19 Rehabilitation Screening Test (C19-YRS) before and after treatment. In addition, plasma levels of pro inflammatory cytokines and chemokines and the post-acute sequelae score of COVID-19 (PASC) were assessed. Safety parameters such as adverse events, haematology, and serum biochemistry were evaluated. Results: Results showed that all COVID-19 survivors had higher FSSQ, C19-YRS, and PASC scores a Long with elevated plasma levels of pro inflammatory cytokines and chemokines before treatment. CelWel supplementation for 14 days significantly reduced FSSQ and C19-YRS scores and plasma cytokine and chemokine levels. Furthermore, with CelWel treatment, PASC scores showed a decreasing trend in 11 (73%) subjects, while 4 subjects showed a reverse trend. All laboratory safety parameters were within the normal range, and no adverse events were reported during the study period. Conclusion: These findings suggest that the CelWel supplement is a viable and safe option for reducing the severity of symptoms in patients with Long COVID.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Diversity & Equality in Health and Care.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalDiversity & Equality in Health and Care
  • SubjectGenetics & Molecular Biology
  • SubjectInfectious Diseases
  • BylineArticles whose byline prints “Alben Sigamani”
  • BylineArticles whose byline prints “Sangeetha Sampath Kumar”
  • BylineArticles whose byline prints “K Sunil Naik”